<DOC>
	<DOC>NCT02805348</DOC>
	<brief_summary>The objective of this study is to assess the long-term safety and efficacy of bixalomer under post-marketed setting.</brief_summary>
	<brief_title>Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Patients with predialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kiklin</keyword>
	<keyword>Bixalomer</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>